How many times a day do patients with lung cancer take cabozantinib?
According to the currently available information, the frequency of taking Cabozantinib (Cabozantinib) for patients with lung cancer is usually once a day. This recommended dose and frequency is based on the experience of multiple clinical trials and clinical practice.
Specifically, the recommended dose of cabozantinib may vary for patients with different types of lung cancer, but generally follows the principle of once-daily administration.
For patients with medullary thyroid cancer, the recommended dose of cabozantinib is 140 mg once daily. For patients with mild to moderate hepatic impairment, the starting dose may be adjusted to 80 mg once daily.

For patients with kidney cancer, liver cancer, and non-small cell lung cancer (NSCLC), the recommended dose of cabozantinib is usually 60 mg once a day. This dose has been shown to be safe and effective in multiple clinical trials.
For lung cancer patients with bone metastases, especially patients with prostate cancer bone metastases, the recommended dose of cabozantinib may be adjusted to 40 mg once daily. This is based on the consideration that patients with bone metastases may require lower doses of drugs to control the disease and reduce adverse effects.
It is worth noting that patients need to strictly abide by medical instructions when taking cabozantinib and take it in accordance with the recommended dosage and frequency. At the same time, because cabozantinib may cause a certain burden on organs such as the liver and kidneys, doctors will also fully consider the patient's liver and kidney function when formulating treatment plans, and make dose adjustments when necessary.
In addition, patients need to closely monitor the occurrence of adverse reactions while taking cabozantinib, such as hypertension, hand-foot syndrome, diarrhea, fatigue, etc. Once serious adverse reactions or intolerance occur, you should seek medical treatment promptly and inform the doctor so that the treatment plan can be adjusted.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)